Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Completed · Phase 1

Conditions studied: Schizophrenia

In brief

A 2-part, crossover design, open-label treatment trial with 4 periods, 4 sequences (Part A) to evaluate MR formulations of CVL-231 and a 2 periods, 2 sequences (Part B) to understand effect of food on CVL-231 exposures from an MR formulation.

Key facts

Study ID

NCT05106309

Run by

Cerevel Therapeutics, LLC

People needed

16

Starts

2021-12-29

Expected to finish

2022-02-24

Last updated by the study team

2022-04-27

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Women of nonchildbearing potential and men 18 to 55 years, inclusive.
• Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, ECG, vital sign measurements, and laboratory test results, as evaluated by the investigator.
• Body mass index of 18.5 to 30.0 kg/m2 and a total body weight >50 kg (110 lbs).
• Sexually active men with a pregnant or a nonpregnant partner of childbearing potential must agree to comply with protocol contraception requirements during treatment and through 7 days post dose. In addition, male participants should not donate sperm for a minimum of 7 days following the last dose of IMP.
• Capable of giving signed informed consent.
• Ability, in the opinion of the investigator, to understand the nature of the trial and comply with protocol requirements.

You may not qualify if…

• Current history of significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, endocrine, hematological, immunological, or neurological disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
• Current or past personal or family history of any psychiatric disorder as classified by DSM-5 criteria.
• Epilepsy or a history of seizures except for a single seizure episode, eg, a childhood febrile seizure, a seizure related to trauma or alcohol withdrawal, or an unexplained loss of consciousness.
• History of moderate to severe substance or alcohol-use disorder (excluding caffeine) within 12 months prior to signing the ICF.
• Serious risk of suicide in the opinion of the investigator
• Receipt of SARS-CoV2 vaccine or booster within 28 days of dosing with CVL-231, or plan to receive SARS-CoV2 vaccination or booster from Screening through 5 days after last dose of CVL-231.
• Have recently been diagnosed with symptomatic COVID-19 or test positive for COVID-19 within 30 days prior to signing the ICF.
• Either of the following:
• History of HIV, hepatitis B, or hepatitis C infection
• Positive result for HIV antibody, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody
• Positive drug screen for illicit drugs or a positive test for alcohol
• 12-lead ECG demonstrating pre-defined abnormalities at Screening and Day -1 based on local evaluation.
• Abnormal clinical laboratory tests or vital sign measurements at the Screening Visit and at Day -1 (check-in) for each period
• Known to be allergic or hypersensitive to the IMP or any of its components.
• Participation in any clinical trial within 90 days prior to signing the ICF.

Where it is running

• Celerion Inc. — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.